Audiomedica.com
Long Overall Survival in Ceritinib-Treated ALK-Positive Lung Cancer
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:00:07
- Mas informaciones
Informações:
Sinopsis
MUNICH—More than four years median overall survival was reported in patients treated with an inhibitor of anaplastic lymphoma kinase (ALK) for their ALK gene rearranged non-small cell lung cancer (NSCLC) in a single-arm phase two study reported at the 2018 …181019 Enriqueta Felip AJO PRODUCTION MASTER
